// App-Quantinova.ai

POS1049 (2021) : EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • P. J. Mease

  • P. Helliwell

  • F. Van den Bosch

  • M. Trivedi

  • M. Alani

  • R. Besuyen

  • L. Gheyle

  • E. Gvozdenovic

  • D. D. Gladman

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Swedish Medical Center, Rheumatology Clinical Research Division, Seattle, United States of America

  • University of Washington, Division of Medical Genetics, Seattle, United States of America

  • University of Sheffield School of Medicine, Sheffield, United Kingdom

  • Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • University of Washington, Rheumatology Department, Seattle, United States of America

  • Galapagos GmbH, Biometrics, Basel, Switzerland

  • Galapagos BV, Clinical Research, Leiden, Netherlands

  • Galapagos NV, Clinical Research, Mechelen, Belgium

  • Galapagos NV, Bioinformatics, Mechelen, Belgium

  • Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada

Locations

  • United Kingdom

  • United States

  • Belgium

  • Switzerland

  • Netherlands

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT03101670

  • NCT03320876

Sponsors

  • Galapagos and Gilead Sciences

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved